Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023 at 12:30 pm EDT
Share
Interpace Biosciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 11.03 million compared to USD 7.4 million a year ago. Net income was USD 0.175 million compared to net loss of USD 3.94 million a year ago. Basic earnings per share from continuing operations was USD 0.09 compared to basic loss per share from continuing operations of USD 0.49 a year ago. Diluted earnings per share from continuing operations was USD 0.09 compared to diluted loss per share from continuing operations of USD 0.49 a year ago. Basic earnings per share was USD 0.04 compared to basic loss per share of USD 0.93 a year ago. Diluted earnings per share was USD 0.04 compared to diluted loss per share of USD 0.93 a year ago.
For the six months, sales was USD 20.85 million compared to USD 15.32 million a year ago. Net income was USD 0.526 million compared to net loss of USD 6.19 million a year ago. Basic earnings per share from continuing operations was USD 0.19 compared to basic loss per share from continuing operations of USD 0.76 a year ago. Diluted earnings per share from continuing operations was USD 0.19 compared to diluted loss per share from continuing operations of USD 0.76 a year ago. Basic earnings per share was USD 0.12 compared to basic loss per share of USD 1.47 a year ago. Diluted earnings per share was USD 0.12 compared to diluted loss per share of USD 1.47 a year ago.
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.